@article{a2e0ef3a659b42cfbe0c6a494c243099,
title = "Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia",
author = "Soun Khountham and Polina Shindiapina and Xiaokui Mo and Curtis Lachowiez and Tracy Wiczer and Luay Mousa and Rogers, {Kerry A.} and Andritsos, {Leslie A.} and Woyach, {Jennifer A.} and Byrd, {John C.} and Spurgeon, {Stephen E.} and Awan, {Farrukh T.}",
note = "Funding Information: FTA has served as a consultant for Abbvie, AstraZeneca, Acerta Pharma, Celgene, Blueprint Medicine, Gilead, Genentech, Janssen, Sunesis, Dava Oncology, Kite Pharma, Karyopharm, Verastem, MEI Pharma, Incyte. JCB is a consultant for AstraZeneca, Genentech, Acerta, and Pharmacyclics. KAR received research funding from Genentech, AbbVie, and Janssen, has consulted for Acerta Pharma, and received travel funding from AstraZeneca. LAA has served as a consultant for AstraZeneca. JAW has consulted for Pharmacyclics and Janssen and receives research funding from Pharmacyclics, Janssen, Morphosys, Karyoparm, Loxo, Abbvie, and Verastem. SES has received research funding from Acerta Pharma, Gilead Sciences Inc., Janssen, Genentech, AstraZeneca, and Bristol Myers Squibb and has provided consulting services to Gilead Sciences, Janssen, Portola Pharmaceuticals and Pharmacyclics Inc.",
year = "2021",
doi = "10.1080/10428194.2020.1838508",
language = "English (US)",
volume = "62",
pages = "716--721",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "3",
}